Amerika Serikat - Inggris - NLM (National Library of Medicine)

xiromed, llc - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate injection, usp is indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection, usp should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of cancer of the breast. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or a history of these conditions. - active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). - liver dysfunction or disease. - estradiol valerate injection, usp should not be used in patients with known hypersensitivity to its ingredients. - known or suspected pregnancy. there is no indication for estradiol valerate injection, usp in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions ).

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

bayer new zealand limited - estradiol valerate 1mg - coated tablet - 1 mg - active: estradiol valerate 1mg excipient: calcium carbonate glycerol as glycerol 85% glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone as polyvidone 700,000   purified talc   sucrose titanium dioxide as titanium dioxide e 171 - hormone replacement therapy (hrt) for the treatment of signs and symptoms of oestrogen deficiency due to the menopause (whether natural or surgically induced).

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - estradiol valerate 1 mg - coated tablet - 1 mg - estradiol valerate 1 mg - estradiol

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - estradiol valerate, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; povidone; purified talc; maize starch - oral contraception. treatment of heavy and/or prolonged menstrual bleeding in women without organic pathology who desire oral contraception.

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - estradiol valerate 3 mg (dark yellow tablet); dienogest 2 mg (red tablet); estradiol valerate 2 mg (red tablet); dienogest 3 mg (light yellow tablet); estradiol valerate 2 mg (light yellow tablet); estradiol valerate 1 mg (dark red tablet); placebo (white tablet) - film-coated tablet - 1 mg + 2 mg - 2 mg + 2 mg - 3 mg + 3 mg - dienogest 2 mg; estradiol valerate 2 mg; estradiol valerate 3 mg; estradiol valerate 2 mg; dienogest 3 mg; estradiol valerate 1 mg; placebo - dienogest and estradiol

Amerika Serikat - Inggris - NLM (National Library of Medicine)

par pharmaceutical, inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 10 mg in 1 ml - delestrogen (estradiol valerate injection, usp) is indicated in the: 1. treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). delestrogen should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). 6. liver dysfunction or disease. 7. delestrogen should not be used in patients with known hypersensitivity to its ingredients. 8. known or suspected pregnancy. there is no indication for delestrogen in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy [see precautions ].

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

orion corporation - estradiol valerate; medroxyprogesterone acetate - tablet - 1 mg/5 milligram(s) - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - estradiol valerate 1 mg; dienogest 2 mg - tablet - 1 mg - 2 mg - estradiol valerate 1 mg; dienogest 2 mg - dienogest and estrogen

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

exeltis germany gmbh - estradiol valerate 1 mg; dienogest 2 mg - film-coated tablet - 1 mg - 2 mg - estradiol valerate 1 mg; dienogest 2 mg - progestogens and estrogens, fixed combinations

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

orion corporation - estradiol valerate; medroxyprogesterone acetate - tablet - 1 mg/2.5 milligram(s) - progestogens and estrogens, fixed combinations; medroxyprogesterone and estrogen